Dec 10, 2020
VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
Nov 09, 2020
VistaGen Therapeutics to Participate in the Guggenheim Healthcare Talks | Idea Forum | 2nd Annual Neuro/Immunology Day
Oct 14, 2020
Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement
Aug 13, 2020
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
Aug 10, 2020
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
Aug 04, 2020
VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration
Jul 31, 2020
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
Jul 23, 2020
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
Jun 29, 2020
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
Jun 25, 2020
VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
May 27, 2020
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
May 18, 2020
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
Apr 28, 2020
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
Mar 25, 2020
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
Feb 20, 2020
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
Feb 13, 2020
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
Feb 11, 2020
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
Jan 30, 2020
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
Nov 14, 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
Nov 07, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview